Research programme: Crimean-Congo haemorrhagic fever virus vaccines - Auro Vaccines
Latest Information Update: 10 Mar 2024
At a glance
- Originator Auro Vaccines
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Crimean-Congo haemorrhagic fever virus infections
Most Recent Events
- 19 Feb 2024 Auro Vaccines files patent for VesiculoVax™ platform (Auro Vaccines pipeline, February 2024)
- 19 Feb 2024 Early research in Crimean-Congo haemorrhagic fever virus infections (Prevention) in USA (unspecified route) (Auro Vaccines pipeline, February 2024)